Table of Contents
The Increasing Number of Therapeutic Drugs, Need for Immediate Relief Drive the Growth of Parenteral and Transdermal Excipients
This study covers in detail the parenteral and transdermal excipients used in the pharmaceutical industry. We have observed that the growing prescription of biologicals that are almost exclusively administered by parenteral routes drives the market growth. Convenience and immediate therapeutic benefits have spurred the growth of transdermal products, which has in-turn increased transdermal excipients. The benefits provided by both product forms are expected to gain market share in the next five years.
-In 2013, the global parenteral excipients segment generated a revenue of $ million, and it is predicted to grow to become $ billion by the year 2018 with a CAGR of %.
-The total global parenteral finished products market is estimated to be worth $billion. Parenteral finished products include vials with sterile liquids or powders to be reconstituted for injection; prefilled syringes, cartridges, or pens; single-dosage vials; multiple-dosage vials; and infusion bottles.
-The transdermal excipients segment is predicted to generate $ million by 2018, growing at a CAGR of %. This market is currently generating a global revenue of $ million.
-The high growth of biological drugs that are exclusively administered only through the parenteral route is driving market growth.
oVial injections make up about % of all parenteral units prescribed globally, with the remainder composed of prefilled syringes and other forms such as cartridges, auto injectors, and pens. Diabetes takes the lion’s share of more than % of injectable units.
-Usage of transdermal patches has recently increased multifold in developed regions such as the United States and Western Europe because of its convenience of use and sustained therapeutic effect. The growth of transdermal is accelerating the growth of transdermal excipients.
-The main restraint hindering market growth is increased cost of production, which is leading to high-priced parenteral and transdermal excipients. High price hinders the adaptation of the product by pharmaceutical companies.
-The key market participants in this market are BASF, Dow Chemicals, and Gattefosse. Other market participants include Cargill and Abitech.
Market Overview—Parenteral Excipients
-Parenteral drugs are pyrogen-free, sterile liquid or solid dosages. They may contain or more active ingredients in the form of single as well as multiple dosages.
-These drugs are administered in the form of injections, intravenous infusions, or implants, and they tend to have improved bioavailability compared to oral solid dosages.
-The first-pass metabolism of a parenteral enhances its bioavailability.
-Excipients such as buffering agents, solubilizing agents, anti-microbial preservatives, and carbohydrate excipients are used exclusively in formulating parenteral drugs.
-Biologic parenterals was a $ billion market globally in 2011. About % of indications for biologic parenterals arise from prescriptions for inflammatory diseases, cancers, infectious diseases, and diabetes.
-The total global parenterals market was estimated to be worth $ billion in 2011. Products in this market can be classified as newer biopharmaceuticals that are almost exclusively available as parenterals and conventional injectables.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
North America Facial Injectables Market: Overview This report on the North America facial injectables market analyzes the current and future prospects of the market. The report comprises an elaborate executive ...
Global Pulmonary Drug Delivery Devices Market: Overview This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report ...
The global injectable drug delivery market, in terms of value, is projected to reach USD 624.50 billion by 2021 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period. The increase ...